Myopia Pipeline Insight
DelveInsight’s, “Myopia – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn't focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. People with myopia can have difficulty clearly seeing a movie or TV screen, a whiteboard in school or while driving. Generally, myopia first occurs in school-age children. Because the eye continues to grow during childhood, it typically progresses until about age 20. However, myopia may also develop in adults due to visual stress or health conditions such as diabetes. Testing for myopia may use several procedures to measure how the eyes focus light and to determine the power of any optical lenses needed to correct the reduced vision. Glasses or contact lenses can correct myopia in children and adults. For adults only (with rare exceptions for children), there are several types of refractive surgeries that can also correct myopia.
"Myopia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.
Myopia Emerging Drugs Chapters
This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myopia Emerging Drugs
Atropine ophthalmic solution, known as MicroPine in US, is developed by Eyenovia, Inc. for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. It is designed based on Eyenovia's Optejet microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP (microdose array print) to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of the drug is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. Atropine micro-formulation licensed to Arctic vision in China, Hong Kong, Macau, Taiwan and South Korea. Atropine micro-formulation licensed to Bausch Health in USA and Canada. The atropine micro formulation is being evaluated in Phase III clinical trials.
Nevakar is developing NVK-002, a novel, investigational, preservative-free low-dose atropine eye drop which is administered nightly, as a single drop to both eyes. NVK-002 uses Nevakar’s proprietary technology, designed for maximum stability and tolerability. Nevakar is currently testing two concentrations in the US and Europe in multiple clinical studies. The product is being studied for up to 4 years to evaluate if it is safe and effective.
Further product details are provided in the report……..
Myopia: Therapeutic Assessment
This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 6+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Eyenovia.
DelveInsight’s report covers around 6+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.
Myopia Report Insights
- Myopia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myopia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myopia drugs?
- How many Myopia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myopia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myopia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myopia and their status?
- What are the key designations that have been granted to the emerging drugs?